Establishment of a Disease-Specific Graded Prognostic Assessment for Hepatocellular Carcinoma Patients with Spinal Metastasis
0
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: Hepatocellular carcinoma (HCC) patients with spinal metastasis (SM) show heterogeneous lengths of survival. In this study, we develop and propose a graded prognostic assessment for HCC patients with SM (HCC-SM GPA). Methods: We previously reported the outcomes of 192 HCC patients with SM who received radiotherapy from April 1992 to February 2012. Prognostic factors that significantly affected survival in that study were used to establish the HCCSM GPA. Validation was performed using an independent cohort of 63 patients recruited from September 2011 to March 2016. Results: We developed the HCC-SM GPA using the following factors: Eastern Cooperative Oncology Group performance status (0–2, 0 point; 3–4, 1 point), controlled primary HCC (yes, 0 point; no, 2 points), and extrahepatic metastases other than bone (no, 0 point; yes, 1 point). Patients were stratified into low (GPA=0), intermediate (GPA=1 to 2), and high risk (GPA=3 to 4). When applied to the validation cohort, the HCC-SM GPA determined median survival durations of 13.6, 4.8, and 2.6 months and 1-year overall survival rates of 58.3%, 17.8%, and 7.3% for the low-, intermediate-, and highrisk patient groups, respectively (p<0.001). Conclusions: Our newly proposed HCC-SM GPA successfully predicted survival outcomes.
Abstract
Background/Aims: Hepatocellular carcinoma (HCC) patients with spinal metastasis (SM) show heterogeneous lengths of survival. In this study, we develop and propose a graded prognostic assessment for HCC patients with SM (HCC-SM GPA). Methods: We previously reported the outcomes of 192 HCC patients with SM who received radiotherapy from April 1992 to February 2012. Prognostic factors that significantly affected survival in that study were used to establish the HCCSM GPA. Validation was performed using an independent cohort of 63 patients recruited from September 2011 to March 2016. Results: We developed the HCC-SM GPA using the following factors: Eastern Cooperative Oncology Group performance status (0–2, 0 point; 3–4, 1 point), controlled primary HCC (yes, 0 point; no, 2 points), and extrahepatic metastases other than bone (no, 0 point; yes, 1 point). Patients were stratified into low (GPA=0), intermediate (GPA=1 to 2), and high risk (GPA=3 to 4). When applied to the validation cohort, the HCC-SM GPA determined median survival durations of 13.6, 4.8, and 2.6 months and 1-year overall survival rates of 58.3%, 17.8%, and 7.3% for the low-, intermediate-, and highrisk patient groups, respectively (p<0.001). Conclusions: Our newly proposed HCC-SM GPA successfully predicted survival outcomes.
참고문헌 (36)
- Fukutomi M, "Increased incidence of bone metastases in hepatocellular carcinoma", Eur J Gastroenterol Hepatol, 13, pp.1083~1088 (2001)
- Santini D, "Natural history of malignant bone disease in hepatocellular carcinoma: final results of a multicenter bone metastasis survey", PLoS One, 9, pp.e105268~ (2014)
- Goodwin CR, "A systematic review of metastatic hepatocellular carcinoma to the spine", World Neurosurg, 91, pp.510~517.e4 (2016)
- 최지환, "Predictive Factors of Palliative Radiotherapy Response and Survival in Patients with Spinal Metastases from Hepatocellular Carcinoma", Gut and Liver, 9(1), pp.94~102 (2015), 거트앤리버 발행위원회
- He J, "Clinical features and prognostic factors in patients with bone metastases from hepatocellular carcinoma after liver transplantation", BMC Cancer, 11, pp.492~ (2011)
- Kim SU, "Hepatocellular carcinoma presenting with bone metastasis: clinical characteristics and prognostic factors", J Cancer Res Clin Oncol, 134, pp.1377~1384 (2008)
- Kaizu T, "Radiotherapy for osseous metastases from hepatocellular carcinoma: a retrospective study of 57 patients", Am J Gastroenterol, 93, pp.2167~2171 (1998)
- Seong J, "Radiotherapy for painful bone metastases from hepatocellular carcinoma", Liver Int, 25, pp.261~265 (2005)
- Joaquim AF, "An update in the management of spinal metastases", Arq Neuropsiquiatr, 73, pp.795~802 (2015)
- Klimo P Jr, "Surgical management of spinal metastases", Oncologist, 9, pp.188~196 (2004)
- Kim JW, "Clinical outcomes of sorafenib treatment in patients with metastatic hepatocellular carcinoma who had been previously treated with fluoropyrimidine plus platinum- based chemotherapy", Am J Clin Oncol, 34, pp.125~129 (2011)
- Nakano M, "Sorafenib for the treatment of advanced hepatocellular carcinoma with extrahepatic metastasis: a prospective multicenter cohort study", Cancer Med, 4, pp.1836~1843 (2015)
- DU J, "Long-term progression-free survival in a case of hepatocellular carcinoma with vertebral metastasis treated with a reduced dose of sorafenib: case report and review of the literature", Oncol Lett, 5, pp.381~385 (2013)
- Min Ho Lee, "Survival-Related Factors of Spinal Metastasis with Hepatocellular Carcinoma in Current Surgical Treatment Modalities : A Single Institute Experience", 대한신경외과학회지, 58(5), pp.448~453 (2015), 대한신경외과학회
- Chang SS, "The clinical features and prognostic factors of hepatocellular carcinoma patients with spinal metastasis", Eur J Gastroenterol Hepatol, 13, pp.1341~1345 (2001)
- Chang UK, "Clinical result of stereotactic radiosurgery for spinal metastasis from hepatocellular carcinoma: comparison with conventional radiation therapy", J Neurooncol, 119, pp.141~148 (2014)
- Sperduto CM, "A validation study of a new prognostic index for patients with brain metastases: the graded prognostic assessment", J Neurosurg, 109(Suppl), pp.87~89 (2008)
- Sperduto PW, "A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1,960 patients in the RTOG database", Int J Radiat Oncol Biol Phys, 70, pp.510~514 (2008)
- Sperduto PW, "Effect of tumor subtype on survival and the graded prognostic assessment for patients with breast cancer and brain metastases", Int J Radiat Oncol Biol Phys, 82, pp.2111~2117 (2012)
- Lim S, "Hepatocellular carcinoma specific graded prognostic assessment can predict outcomes for patients with brain metastases from hepatocellular carcinoma", J Neurooncol, 120, pp.199~207 (2014)
- Tokuhashi Y, "A revised scoring system for preoperative evaluation of metastatic spine tumor prognosis", Spine (Phila Pa 1976), 30, pp.2186~2191 (2005)
- Tomita K, "Surgical strategy for spinal metastases", Spine (Phila Pa 1976), 26, pp.298~306 (2001)
- Fourney DR, "Spinal instability neoplastic score: an analysis of reliability and validity from the spine oncology study group", J Clin Oncol, 29, pp.3072~3077 (2011)
- Ditunno JF Jr, "The international standards booklet for neurological and functional classification of spinal cord injury: American Spinal Injury Association", Paraplegia, 32, pp.70~80 (1994)
- Kleinbaum DG, "Survival analysis: a self-learning text" (1996), Springer-Verlag
- Chow E, "Predictive model for survival in patients with advanced cancer", J Clin Oncol, 26, pp.5863~5869 (2008)
- Chow E, "Predictive model for survival in patients having repeat radiation treatment for painful bone metastases", Radiother Oncol, 118, pp.547~551 (2016)
- Seil Sohn, "Radiosurgery Compared with External Radiation Therapy as a Primary Treatment in Spine Metastasis from Hepatocellular Carcinoma : A Multicenter, Matched-Pair Study", 대한신경외과학회지, 59(1), pp.37~43 (2016), 대한신경외과학회
- Aoude A, "A comparison of the modified Tokuhashi and Tomita scores in determining prognosis for patients afflicted with spinal metastasis", Can J Surg, 57, pp.188~193 (2014)
- Kim CH, "Surgical outcome of spinal hepatocellular carcinoma metastases", Neurosurgery, 68, pp.888~896 (2011)
- 이은주, "Clinical outcomes of stereotactic body radiotherapy for spinal metastases from hepatocellular carcinoma", Radiation oncology journal, 33(3), pp.217~225 (2015), 대한방사선종양학회
- Wang XS, "Stereotactic body radiation therapy for management of spinal metastases in patients without spinal cord compression: a phase 1-2 trial", Lancet Oncol, 13, pp.395~402 (2012)
- Niibe Y, "Oligometastases and oligo-recurrence: the new era of cancer therapy", Jpn J Clin Oncol, 40, pp.107~111 (2010)
- Hellman S, "Oligometastases", J Clin Oncol, 13, pp.8~10 (1995)
- Ahmed KA, "Stereotactic body radiotherapy in the management of oligometastatic disease", Cancer Control, 23, pp.21~29 (2016)
- Dagan R, "A multi-national report on stereotactic body radiotherapy for oligometastases: patient selection and follow-up", Acta Oncol, 55, pp.633~637 (2016)